Drugs /
ff-21101
Overview
Clinical Trials
Ff-21101 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ff-21101, 1 is phase 1 (1 open).
ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for ff-21101 clinical trials.
Breast carcinoma, cholangiocarcinoma, and colorectal carcinoma are the most common diseases being investigated in ff-21101 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.